1. 12-Month Outcomes of Goniotomy Performed Using the Kahook Dual Blade Combined with Cataract Surgery in Eyes with Medically Treated Glaucoma
- Author
-
Gabriel Lazcano-Gomez, Jason K. Darlington, Syril Dorairaj, John P. Berdahl, Leonard K. Seibold, Jesus Jimenez-Roman, Ahmad A. Aref, Nathan M. Radcliffe, and Kaweh Mansouri
- Subjects
Intraocular pressure ,medicine.medical_specialty ,genetic structures ,medicine.medical_treatment ,Pharmacology toxicology ,Visual Acuity ,Glaucoma ,Trabeculectomy ,Cataract surgery ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Ophthalmology ,medicine ,Glaucoma surgery ,Humans ,Pharmacology (medical) ,Case Series ,Postoperative Period ,Prospective Studies ,Trabecular meshwork ,Adverse effect ,Phacoemulsification ,business.industry ,Micro-incisional glaucoma surgery ,General Medicine ,medicine.disease ,Rheumatology ,eye diseases ,Micro-invasive glaucoma surgery ,Treatment Outcome ,030221 ophthalmology & optometry ,Goniotomy ,sense organs ,business ,030217 neurology & neurosurgery - Abstract
Introduction To describe the 12-month efficacy and safety of goniotomy performed using the Kahook Dual Blade (KDB) in combination with cataract surgery in eyes with medically treated open-angle glaucoma (OAG). Methods This was a prospective, interventional case series conducted at seven centers in North America. Consecutive patients with medically treated OAG and visually significant cataract underwent phacoemulsification combined with goniotomy (PE + goniotomy) using KDB. Indications for glaucoma surgery included reduction of intraocular pressure (IOP) and reduction of IOP-lowering medications. De-identified data were collected and included pre-, intra-, and postoperative data on IOP, the use of IOP-lowering medications, and adverse events through 12 months of follow-up. Results Among 52 eyes undergoing surgery, mean IOP was reduced from 16.8 ± 0.6 mmHg at baseline to 12.4 ± 0.3 mmHg at month 12 (P 10 mmHg (n = 2, 3.8%). Conclusion PE + goniotomy using the KDB significantly lowers both IOP and dependence on IOP-lowering medications in eyes with OAG. Adverse events were not sight-threatening and typically resolved spontaneously. Funding New World Medical, Inc.
- Published
- 2018